During the past decade, Chancellor Center for Oncology conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 18 clinical trials were completed, i.e. on average, 47.4% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 18 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chancellor Center for Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 19 trials, followed by "Alliance for Clinical Trials in Oncology" with 11 trials sponsored, "SWOG Cancer Research Network" with 6 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 5 trials sponsored and "NRG Oncology" with 5 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chancellor Center for Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 26 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "Astellas Pharma US, Inc." with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Chancellor Center for Oncology" are "Stage IIIA Breast Cancer" (5 trials), "Invasive Breast Carcinoma" (4 trials), "Stage II Breast Cancer" (4 trials), "Recurrent Squamous Cell Lung Carcinoma" (3 trials) and "Stage IIA Breast Cancer" (3 trials). Many other conditions were trialed in "Chancellor Center for Oncology" in a lesser frequency.

Most popular intervention types in "Chancellor Center for Oncology" are "Drug" (35 trials), "Other" (27 trials), "Procedure" (16 trials), "Biological" (15 trials) and "Radiation" (6 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (17 trials), "Quality-of-Life Assessment" (9 trials), "Biospecimen Collection" (8 trials), "Computed Tomography" (8 trials) and "Nivolumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Chancellor Center for Oncology" are 39 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Chancellor Center for Oncology". undefined are not yet recruiting, 7 are recruiting, 30 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Chancellor Center for Oncology, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Chancellor Center for Oncology, 1 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".